These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases: JACC State-of-the-Art Review. Del Buono MG; Montone RA; Camilli M; Carbone S; Narula J; Lavie CJ; Niccoli G; Crea F J Am Coll Cardiol; 2021 Sep; 78(13):1352-1371. PubMed ID: 34556322 [TBL] [Abstract][Full Text] [Related]
6. Endothelial Autophagy in Coronary Microvascular Dysfunction and Cardiovascular Disease. Zhao F; Satyanarayana G; Zhang Z; Zhao J; Ma XL; Wang Y Cells; 2022 Jun; 11(13):. PubMed ID: 35805165 [TBL] [Abstract][Full Text] [Related]
7. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob Adingupu DD; Göpel SO; Grönros J; Behrendt M; Sotak M; Miliotis T; Dahlqvist U; Gan LM; Jönsson-Rylander AC Cardiovasc Diabetol; 2019 Feb; 18(1):16. PubMed ID: 30732594 [TBL] [Abstract][Full Text] [Related]
8. Physiological Stratification of Patients With Angina Due to Coronary Microvascular Dysfunction. Rahman H; Demir OM; Khan F; Ryan M; Ellis H; Mills MT; Chiribiri A; Webb A; Perera D J Am Coll Cardiol; 2020 May; 75(20):2538-2549. PubMed ID: 32439003 [TBL] [Abstract][Full Text] [Related]
9. Differential Pathophysiological Mechanisms in Heart Failure With a Reduced or Preserved Ejection Fraction in Diabetes. Packer M JACC Heart Fail; 2021 Aug; 9(8):535-549. PubMed ID: 34325884 [TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Wang D; Luo P; Wang Y; Li W; Wang C; Sun D; Zhang R; Su T; Ma X; Zeng C; Wang H; Ren J; Cao F Diabetes; 2013 May; 62(5):1697-708. PubMed ID: 23364453 [TBL] [Abstract][Full Text] [Related]
11. Role of Inflammation in Coronary Epicardial and Microvascular Dysfunction. Godo S; Takahashi J; Yasuda S; Shimokawa H Eur Cardiol; 2021 Feb; 16():e13. PubMed ID: 33897839 [TBL] [Abstract][Full Text] [Related]
12. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264 [TBL] [Abstract][Full Text] [Related]
13. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Paulus WJ; Tschöpe C J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677 [TBL] [Abstract][Full Text] [Related]
14. GLP-1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes. Love KM; Liu J; Regensteiner JG; Reusch JEB; Liu Z J Diabetes; 2020 Jul; 12(7):488-498. PubMed ID: 32274893 [TBL] [Abstract][Full Text] [Related]
15. Coronary microvascular dysfunction: A review of recent progress and clinical implications. Rehan R; Yong A; Ng M; Weaver J; Puranik R Front Cardiovasc Med; 2023; 10():1111721. PubMed ID: 36776251 [TBL] [Abstract][Full Text] [Related]
16. Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction. Ahmad A; Corban MT; Toya T; Verbrugge FH; Sara JD; Lerman LO; Borlaug BA; Lerman A Eur J Heart Fail; 2021 May; 23(5):765-772. PubMed ID: 32949186 [TBL] [Abstract][Full Text] [Related]